Mardia Samyoung Capillary Tubes Company Ltd

Price story Before the numbers, the tape. A stock price moves through four repeating seasons: a flat base (stage 1), an advance (2), a top (3), a decline (4). Where the price sits in that cycle frames everything below.

Mardia Samyoung Capillary Tubes Company Ltd trades at ₹104, in a confirmed uptrend and 63 weeks into that stage. That is +99.3% against its own 200-day average. It sits at 83% of a 52-week range of ₹8 to ₹123. On relative strength it is currently behind the NIFTY 500 on a trailing-13-week view (6 weeks and counting).

Today the stock is in a confirmed uptrend — week 63 of stage 2, confirmed. At ₹104 it trades +99.3% versus its 200-day average and sits at 83% of its 52-week range (₹8–₹123).

Against the market, two honest reads. Cumulative: over the last 9.9 years the stock moved +836% while the NIFTY 500 moved +242% — ahead of the index over the full window. Recent form: on a trailing-13-week view the stock is currently behind (6 weeks and counting; last ahead the week of 2026-01-19) — the ribbon below is that same metric, week by week.

What would end the trend, mechanically: two Friday closes in a row below the 200-day line. That is the exit rule — no debates.

→ The trend is one thing; the bill is another. Are you paying up for it? Next: how the P/E reads against its own history.

Valuation P/E is the price of ₹1 of annual profit: how many rupees the market pays for each rupee the company earns in a year.

Mardia Samyoung Capillary Tubes Company Ltd trades at 687.0× P/E, against too little history to rank. Its long-run median P/E is 307.0×, measured across 9.2 years of weekly readings. This places the multiple against the stock’s own record, and says nothing about what the business is worth.

Today's P/E of 687.0× is against too little history to rank, against a long-run median of 307.0× measured over 9.2 years of weekly readings. This is a comparison against the stock's own history — not a claim about what it is worth.

Put together: the multiple is unremarkable against its own past, so the story rests on the earnings line underneath it, not the multiple.

→ Cheap or dear rides on the earnings. Are they actually growing? Next: the fundamental stage — where the business sits in its arc, and how growth has compounded.

Stage: No read Every business sits somewhere on a fundamental arc, and this page names the spot before anything else. The last twelve quarters of revenue, profit and EPS growth — plus the return the business earns on its capital — are read as curves: Deteriorating (the curves are falling), Turning around (a trough has just formed and the last few quarters lift off it), Improving (the climb off the trough is sustained), Consistent (steadily positive with healthy returns), Topping out (still high but decelerating from the peak). When the curves genuinely disagree the read is Mixed; too little history is No read. CAGR (compound annual growth rate) is the smooth yearly pace that turns the starting value into the latest one — the fairest way to compare growth across different time spans. Read the columns together: if the 1-year number towers over the 10-year, recent growth is running hotter than the long-run trend. A dash means that window is not held, or the base year was a loss (where a growth rate is not meaningful).

Mardia Samyoung Capillary Tubes Company Ltd reads as no read on its fundamental arc. Under eight usable quarters on the growth trio — not enough history for an honest trajectory read. The read is built from 4 quarters across 1 curve, on partial evidence.

Why it matters: with too little history, an honest page says so instead of guessing a trajectory.

Return readings here are annual, not quarterly — read as level and direction only; they can confirm the growth curves but never drive the stage on their own.

Fewer than eight usable quarters on the growth curves — this page will not guess a trajectory from a stub of history.

→ The stage names the trajectory. Next: the revenue line that produces it, quarter by quarter.

4-Factor Sector Score

58.2/100 — rank 39 of 48 in Trading · 33% evidence confidence · provisional, ranked below fully-evidenced peers

Mardia Samyoung Capillary Tubes Company Ltd scores 58.2 out of 100 against the 48 companies it is compared with in Trading, ranking 39. Fill the missing evidence before acting; the ranking is deliberately pulled toward neutral.

The four contributions add to the total exactly: 20.5 + 16.7 + 8.7 + 12.3 = 58.2. This is the SAME number shown on the sector comparison — it is computed once, for the whole peer set, and read here.

What would change it: The read weakens if profit growth turns negative or margin improvement reverses while sector-relative strength deteriorates.

Revenue Revenue is the top line: everything the company billed its customers in the period.

Mardia Samyoung Capillary Tubes Company Ltd reported ₹12.3 Cr of revenue in the Dec 25 quarter. The last full year, FY25, came in at ₹0.0 Cr. The last four reported quarters add to ₹12.8 Cr. A multi-year compound rate is not shown because the annual history behind it is too short to compute one honestly.

Mardia Samyoung Capillary Tubes Company Ltd reported ₹12.3 Cr of revenue in the Dec 25 quarter. The last full year, FY25, came in at ₹0.0 Cr. The last four reported quarters add to ₹12.8 Cr. A multi-year compound rate is not shown because the annual history behind it is too short to compute one honestly.

FY25 revenue came in at ₹0.0 Cr (null on the year). The latest quarter (Dec 25) printed ₹12.3 Cr, null year on year.

→ Revenue slipped — did margins hold as it scaled? Next: 15.3% this quarter (null pp YoY).

Operating margin Operating margin is what is left of every ₹100 of sales after running the business, before interest and tax. It is the cleanest read on pricing power and cost control.

Mardia Samyoung Capillary Tubes Company Ltd's operating margin is 15.3% in the Dec 25 quarter. Across 5 fiscal years the operating margin has ranged −150.8% to 4,000.0%. The current quarter sits inside that band.

Mardia Samyoung Capillary Tubes Company Ltd's operating margin is 15.3% in the Dec 25 quarter. Across 5 fiscal years the operating margin has ranged −150.8% to 4,000.0%. The current quarter sits inside that band.

The latest quarter's operating margin is 15.3%, null pp against the same quarter a year ago. Across 5 fiscal years the operating margin has ranged −150.8%–4,000.0%.

Why: the numbers show the operating margin move clearly, but the cost lines behind it sit below what we hold — so we state the move without inventing its driver.

→ Margins slipped — did that reach the bottom line? Next: profit null in the latest quarter.

Net profit Net profit is what survives every cost, interest and tax — the number EPS, dividends and book value all grow from.

Mardia Samyoung Capillary Tubes Company Ltd earned ₹1.3 Cr of net profit in the Dec 25 quarter. Full-year FY25 profit was ₹1.2 Cr. That is 10.4% of the quarter's revenue. The same quarter a year earlier lost ₹0.1 Cr. 10 of the last 12 reported quarters were loss-making.

Mardia Samyoung Capillary Tubes Company Ltd earned ₹1.3 Cr of net profit in the Dec 25 quarter. Full-year FY25 profit was ₹1.2 Cr. That is 10.4% of the quarter's revenue. The same quarter a year earlier lost ₹0.1 Cr. 10 of the last 12 reported quarters were loss-making.

Dec 25 profit was ₹1.3 Cr, null year on year. On the full year, FY25 printed ₹1.2 Cr (null).

→ Profit rose — but did the cash follow? Next: −206% of the last 2 years' profit arrived as cash.

Cash flow — the router The P&L says what was earned; the cash-flow statement says what actually arrived. Operating cash flow (CFO) against profit is the cleanest lie detector in the accounts.

Over the last 2 fiscal years −206% of Mardia Samyoung Capillary Tubes Company Ltd's reported profit arrived as operating cash — a gap worth watching. In FY25 that was ₹−2.5 Cr of operating cash against ₹1.2 Cr of profit. After ₹−3.0 Cr of capital spending, ₹0.0 Cr was left as free cash.

FY25: operating cash of ₹−2.5 Cr against reported profit of ₹1.2 Cr, leaving free cash of ₹0.0 Cr after ₹−3.0 Cr of capital spending. Across the last 2 fiscal years the conversion rate is −206% of profit.

Cash-flow readings here are annual — that is the resolution our series carries, so this section moves once a year.

🚨 Why conversion sits at −206%: the cash cycle tightened 4,478 days between FY14 and FY24 — cash that used to wait in the cycle now reaches the bank sooner. Less than 70% of profit arriving as cash is the thing to watch on this page.

Router verdict: no single sink dominates — the next section checks both the working-capital cycle and the capital spending.

→ So follow the cash to where it goes. Next: a −1,929-day cycle and ₹−2.0 Cr of building.

Where the cash goes Working capital is the cash tied up between paying suppliers and getting paid: debtor days (customers owe), inventory days (stock waits), and the cash conversion cycle (the whole loop, in days of sales).

Mardia Samyoung Capillary Tubes Company Ltd's cash conversion cycle runs −1,929 days in FY24, down from 2,549 days in FY14. Capital spending ran ₹−2.0 Cr over the last 3 years. Customers take 0 days to pay and stock waits −1,929 days to sell.

FY24: debtors at 0 days, inventory at −1,929 days — roughly −63.5 months of stock waiting to sell; that is where the cash sits while it waits — for a full cycle of −1,929 days, tighter than FY14's 2,549.

On the investment side: capital spending of ₹−2.0 Cr over the last 3 fiscal years. Capital work-in-progress stands at ₹0.0 Cr (FY25) — capacity paid for but not yet earning.

The synthesis: neither the cycle nor the build-out is hoarding the cash — the machine is reasonably clean.

→ Does all this activity actually earn its cost of capital? Next: ROCE is 23%.

Return on capital Return on capital employed (ROCE) is the profit the whole business earns on all the money in it — equity and debt together. It is the single best test of whether growth creates value or just size.

Mardia Samyoung Capillary Tubes Company Ltd earns a ROCE of 23% in FY25. That is up from a trough of −10% in FY24. A return-on-invested-capital spread against the cost of capital is not computable from what is held here. The wiring behind it is 364.3% net margin on −0.02× asset turns.

FY25 ROCE is 23%, recovered from a FY24 trough of −10% — the full ladder below shows the fall and the climb, undoctored.

Why the return is what it is — the wiring (FY24): 364.3% net margin × −0.02× asset turns × 1.54× balance-sheet leverage ≈ −11.2% on equity. Margin is doing the heavy lifting; leverage is modest — this is an earned return, not a borrowed one.

→ Returns like these — is the balance sheet borrowing to make them? Next: debt-to-equity is 0.00.

Debt Debt-to-equity says how much of the business is funded by borrowings; interest cover says how many times operating profit pays the interest bill. Low and high, respectively, is the safe corner.

Mardia Samyoung Capillary Tubes Company Ltd carries ₹0.0 Cr of borrowings against ₹5.6 Cr of equity in FY25, a debt-to-equity of 0.00. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr. Capital spending ran ₹−2.0 Cr across the last 3 of those years.

FY25: borrowings of ₹0.0 Cr against equity of ₹5.6 Cr — a debt-to-equity of 0.00. Over 5 years borrowings went from ₹0.0 Cr to ₹0.0 Cr while capital spending ran ₹−2.0 Cr in just the last 3 — the build-out is being paid for out of cash, not debt.

→ Who owns this, and are they adding or leaving? Next: the register is quiet.

Ownership Who owns the stock, quarter by quarter: promoters (the controlling owners), foreign and domestic institutions, and the public. Steady accumulation by people close to the numbers is a signal; a quiet register is also an answer.

No holder of Mardia Samyoung Capillary Tubes Company Ltd moved a full percentage point over the last two years — the register is quiet. Domestic institutions moved +0.0 points over the same window, to 0.1%. The register is read on the four disclosed classes only; nothing is inferred between filings.

The register over the last two years — Promoters: +0.0 points over 8 quarters to 69.4%; Domestic institutions: +0.0 points over 8 quarters to 0.1%.

→ One last check: does the safety math agree? Next: the balance-sheet safety line.

Safety line The Z-score estimates how far a company sits from balance-sheet distress — above roughly 3 is safe, below roughly 1.8 is the danger zone. It was built for manufacturers, so it is not applied to banks and lenders.

Mardia Samyoung Capillary Tubes Company Ltd: the Z-score is not available for this stock, so we say so rather than invent one. It is a distance-to-distress estimate from the balance sheet, not a forecast of failure. The debt, cash-flow and return sections above carry the balance-sheet evidence this page does hold, and each of them states its own reporting date.

The safety line in one sentence: the Z-score is not available for this stock, so we say so rather than invent one.

Frequently asked questions